Kristen Lauing to Humans
This is a "connection" page, showing publications Kristen Lauing has written about Humans.
Connection Strength
0.082
-
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clin Cancer Res. 2023 12 01; 29(23):4973-4989.
Score: 0.008
-
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. J Med Chem. 2022 12 08; 65(23):15642-15662.
Score: 0.007
-
Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 07; 10(7).
Score: 0.007
-
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.
Score: 0.007
-
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245.
Score: 0.006
-
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185.
Score: 0.006
-
Quantification of IDO1 enzyme activity in normal and malignant tissues. Methods Enzymol. 2019; 629:235-256.
Score: 0.006
-
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). Oncoimmunology. 2019; 8(3):1548242.
Score: 0.005
-
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018 06 01; 24(11):2559-2573.
Score: 0.005
-
IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018 May; 15(5):447-457.
Score: 0.005
-
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017 Nov 01; 23(21):6650-6660.
Score: 0.005
-
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015 Dec 15; 21(24):5427-33.
Score: 0.004
-
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. J Clin Neurosci. 2015 Dec; 22(12):1964-8.
Score: 0.004
-
The role of IDO in brain tumor immunotherapy. J Neurooncol. 2015 Jul; 123(3):395-403.
Score: 0.004
-
Alcohol exposure and mechanisms of tissue injury and repair. Alcohol Clin Exp Res. 2011 Mar; 35(3):392-9.
Score: 0.003